Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation

Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation

Acute graft-versus-host disease (aGVHD) and cytomegalovirus reactivation are important complications after allogeneic stem cell transplantation (alloHSCT). Here, we evaluated the impact of treatment with alemtuzumab on the occurrence of aGVHD, cytomegalovirus reactivation and survival after alloHSCT...

Full description

Bibliographic Details
Main Authors: C.B. Resende, B.M. Rezende, P.T.T. Bernardes, G.M. Teixeira, M.M. Teixeira, V. Pinho, H. Bittencourt
Format: Article
Language:English
Published: Associação Brasileira de Divulgação Científica
Series:Brazilian Journal of Medical and Biological Research
Subjects:
Hematopoietic stem cell transplantation
Alemtuzumab
Graft-versus-host disease
Cytomegalovirus
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017000200705&lng=en&tlng=en

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017000200705&lng=en&tlng=en

Similar Items